[pending] OMNIPAQUE (IOHEXOL)
Pending LLM rewrite. Source: FDA_DRUG D-0447-2026.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Pending LLM scoring against the rubric.
Plain-English summary
Presence of particulate matter
The recalled product
- Product
- OMNIPAQUE (IOHEXOL)
- Brand
- OMNIPAQUE
- Manufacturer
- GE Healthcare Ireland Limited
- Category
- Drug — Drugs
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot# 17225029
- Exp. September 3
- 2028 Lot# 17265376
- Exp. October 3
- 2028 Lot# 17270885
- Exp. September 10
- 2028 Lot# 17292246
- Exp. October 4
- 2028 Lot# 17301805
- Exp. October 18
- 2028 Lot# 17301807
- Exp. September 7
- 2028 Lot# 17301810
- Exp. October 20
- 2028 Lot# 17304992
- Exp. October 5
- 2028 Lot# 17304993
- Exp. October 19
- 2028 Lot# 17304996
- Exp. November 25
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateGasco Isopropyl Alcohol 70% recalled for subpotent drug content
FDA (Drugs) · 2026-07-15
- ModerateGasco Isopropyl Alcohol 70% Recalled for Subpotent Drug Content
FDA (Drugs) · 2026-07-15
- ModerateGasco Isopropyl Alcohol 70% recalled nationwide for subpotency
FDA (Drugs) · 2026-07-15
- ModerateMethohexital Sodium for Injection Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-15